OncoMatch/Clinical Trials/NCT05679921

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Is NCT05679921 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies pembrolizumab, pazopanib for soft tissue sarcoma.

Phase 2RecruitingYonsei UniversityNCT05679921Data as of May 2026

Treatment: pembrolizumab, pazopanib — This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 2 prior lines

Min 1 prior line

Must have received: chemotherapy

progression to 1 or 2 (less than 3) prior chemotherapy

Cannot have received: Programmed Death-1 (PD-1) inhibitor

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: Programmed Death-Ligand 1 (PD-L1) inhibitor

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: Programmed Death-Ligand 2 (PD-L2) inhibitor

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: stimulatory/co-inhibitory T-cell receptor therapy

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Cannot have received: VEGFR inhibitor (pazopanib)

Any previous treatment with a Programmed Death-1(PD1) or Programmed Death-Ligand1(PD-L1) inhibitor, anti-PD-L2 agent, stimulatory/co-inhibitory T-cell receptor (eg. CTLA-4, OX-40, CD137), and/or pazopanib

Lab requirements

Blood counts

Hemoglobin ≥9.0 g/dL; ANC ≥ 1500/mm3; Platelet count ≥ 100,000/mm3

Kidney function

Creatinine ≤1.5 x ULN

Liver function

Serum bilirubin ≤1.5 x institutional ULN; AST/ALT ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN

Adequate normal organ and marrow function as defined below -Hemoglobin ≥9.0 g/dL -Absolute neutrophil count (ANC) ≥ 1500 per mm3 -Platelet count ≥ 100,000 per mm3 -Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). -Aspartate Aminotransferase (AST, SGOT)/Alanine Aminotransferase (ALT, SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN -Creatinine≤1.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify